Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

830

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

September 30, 2029

Conditions

Metabolic Dysfunction-Associated Steatotic Liver DiseaseChronic Hepatitis B

Interventions

DRUG

Peg-IFN α-2b combined with NAs

Peg-IFN α-2b (1.5 μg/kg/week) combined with NAs

All Listed Sponsors

lead

Shenzhen Third People's Hospital

OTHER